Orthocell has appointed its first Canadian distributor for Remplir™, signalling the commencement of the Company’s commercial roll out in the US$75m Canadian nerve repair market.
Following Health Canada’s approval of the Medical Device Licence for Remplir in April, the Company has now secured exclusive distributorships for Alberta and British Columbia, with further appointments anticipated for additional provinces to ensure broad Canadian market coverage.
Official launch activities will commence in early October at the prestigious Annual Meeting of the American Society for Surgery of the Hand (ASSH) in Vancouver, which will be attended by Orthocell’s commercial team.
Orthocell CEO and MD, Paul Anderson said:
“Securing our first Canadian distributor provides immediate access to key provinces and will build Remplir’s profile as a next-generation nerve repair solution. This is a major step in accelerating Remplir’s international growth and our team is looking forward to supporting Canadian clinicians in delivering improved patient outcomes.
“Our existing US Marketing and Medical Education teams are ideally placed to oversee our Canadian market entry given the significant crossover between jurisdictions with many surgeons operating in both countries.
“We expect to see early surgical cases commence in Canada late this year.”